

Registration Form

Name on Certificate/Badge: _____

Department and Institute: _____

Medical Council Registration Number (if applicable): _____

(MCI/State) with which registered: _____

Address for Correspondence: _____

_____ (6 digit) Pin Code: _____

Number 1) Land Line: _____ 2) Mobile: _____

Email id: 1) _____ 2) _____

Payment Details

Amount: _____ Cheque/Draft No. _____

Drawn on Bank: _____ Dated: _____

In case you wish to make the payment online via NEFT, please email us at 3rdLungMCMC@gmail.com and we shall send you the relevant details for the same

Registration Fee for the Course

All fees mentioned are in Indian Rupees and include 18% GST as per Govt of India regulations	Upto December 15, 2017 OR Till First 75 registrations (whichever is earlier)	16 December 2017 to 31 January 2018 OR Till First 150 registrations (whichever is earlier)	February 01, 2018 onwards OR 151st registration onwards (whichever is earlier)
Postgraduate Students, Residents, Fellows and others in training	Rs. 1750/-	Rs. 2300/-	Rs. 2900/-
Physicians, Surgeons and other health care professionals in practice	Rs. 2900/-	Rs. 3500/-	Rs. 4200/-

For Post graduate students/residents/fellows, registration form should be accompanied by a certificate regarding status of being in-training from either the Director/Principal of the Institute or Head of Department in which he/she is enrolled

Kindly make multicurrency cheque or bank draft (payable at Chandigarh, India) in favor of "Lung Cancer Education Society" [Outstation cheques will not be accepted]
Send your registration form and payment (by post or email) to

Office of Department of Pulmonary Medicine, Room No 17-A, Level IV, F Block, Nehru Hospital, PGIMER, Sector 12, Chandigarh, India – 160012
Contact Details: +91-172-275-6820, 26, 28
Email: 3rdLungMCMC@gmail.com

- The course will be accredited by the Punjab Medical Council.
- Registration fee includes lunches/refreshment breaks on both days and dinner on day 1
- Registration fee is non-refundable. However, under exceptional circumstances, requests for transfer of registration to a colleague shall be assessed on a case-to-case basis
- Receipt will be sent by e-mail at the email address(es) written on the registration form

International Faculty

Medical Oncology



Dr. Tony SK Mok MD FRCP

Chairman, Department of Clinical Oncology
Li Shu Fan Professor of Clinical Oncology,
Chinese University of Hong Kong & Past President of the IASLC

Molecular Pathology



Dr. Ming Sound Tsao, MD, FRCP

Consultant Thoracic Pathologist & Senior Scientist,
Princess Margaret Cancer Centre
Professor of Laboratory Medicine & Pathobiology / Medical Biophysics
and the M. Qasim Choksi Chair in Lung Cancer
Translational Research University of Toronto, Canada

Radiation Oncology



Dr. Suresh Senan MRCP, FRCP, PhD

Professor of Clinical Experimental
Radiotherapy and Vice-chairman, Department of Radiation Oncology,
VU University Medical Center, Amsterdam, Netherlands

Surgical Oncology



Dr. Ramon Rami-Porta MD

Clinical Chief, Thoracic Surgery Service,
Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain
& Past-Chairman, Staging and Prognostic Factors Committee of the IASLC

Further information about the course (including agenda and registration) is also available at www.isslc.org ; <http://www.asco.org/calendar> and <http://www.asco.org/international-programs>

3rd Lung MCMC

Multidisciplinary Cancer Management Course

A joint initiative of ASCO, ISSLC, PGIMER and TMC in
Collaboration with the Lung Cancer Education Society



Dates : March 24-25, 2018

Venue : PGIMER, Chandigarh, India

Organized by :

Indian Society for Study of Lung Cancer (ISSLC)

**Department of Pulmonary Medicine,
PGIMER, Chandigarh**

Lung Cancer Education Society



**ISSLC, Lung Cancer Education Society
and PGIMER, Chandigarh
welcome you to the 3rd Lung MCMC**



Dear friends,

Lung cancer is the most common cause of cancer related death globally and in India. Globally it is estimated that **seven patients are diagnosed with lung cancer every two minutes and that three patients die from this disease every minute**. Lung cancer is responsible for one in every five cancer-related deaths. Most lung cancer patients present in an advanced stage and one of the reasons for this is late referrals to oncologists. Delays in diagnosis of this disease result from lack of awareness as well as an overlap of clinical and radiological features with other pulmonary disorders. The silver lining to this is that enormous progress has been made in management of lung cancer in the last decade especially in the metastatic setting. In particular, targeted therapies and immunotherapy have revolutionized the management of metastatic non-small cell lung cancer (including lung adenocarcinoma).

In this context, we are pleased to inform you that as a result of the **encouraging feedback received from the previous two versions of ASCO-ISSLC Lung Multidisciplinary Cancer Management Course (MCMC) held at PGIMER, Chandigarh (April 2014) and at Tata Memorial Hospital, Mumbai (March 2016), the 3rd version of this ASCO-ISSLC Lung MCMC will be held on March 24-25, 2018 at PGIMER, Chandigarh**. Prof. Tony Mok, a world renowned medical oncologist, from the Chinese University of Hong Kong is the course director for this MCMC and will be participating as one of the ASCO faculty. He will be joined by other world renowned experts - **Dr. Ramon Rami-Porta from Spain, Prof. Suresh Senan from Netherlands and Prof. Ming Tsao from Canada**.

This meeting aims to provide a comprehensive overview of the current evidence in the management of lung cancer with perspectives being provided by pathologists, molecular biologists, radiologists, thoracic surgical oncologists, radiation oncologists, medical oncologists, pulmonologists and palliative care experts. The **highlight of this course**, as for the previous two courses would be a focus on **multi-disciplinary management of lung cancer** and in particular, **case discussions by multi-disciplinary tumor boards and molecular tumor boards** comprised of the international (ASCO) faculty as well as eminent national faculty (including those from the two collaborating institutes - PGIMER, Chandigarh and Tata Memorial Hospital, Mumbai). Please view the full agenda and other details at www.isslc.org. The registration and payment can be done online directly at www.isslc.org or offline (registration form provided in the brochure). For any other queries, please feel free to contact us at 3rdLungMCMC@gmail.com

We look forward to welcoming you to this event in March 2018.



**Program Director
Dr. Tony SK Mok**

Prof. Tony S. K. Mok was trained in medical oncology and worked as a community oncologist in Canada for seven years before returning to Hong Kong in 1996 to pursue an academic career. He is currently Li Shu Fan Professor of Clinical Oncology and Chairman, Department of Clinical Oncology at the Chinese University of Hong Kong. His main research interest

focuses on biomarker and molecular targeted therapy in lung cancer. He has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutations. Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Lancet and Journal of Clinical Oncology. He is the Past President of the International Association for Study of Lung Cancer, Past Chair of ASCO's International Affairs Committee and Vice Secretary of the Chinese Society of Clinical Oncology.



**President ISSLC
Dr. D. Behera MD**

Senior Professor of Pulmonary Medicine,
and Dean – Research, PGIMER, Chandigarh



Dr. Ashutosh N. Aggarwal MD DM
Professor and Head,
Department of Pulmonary Medicine,
PGIMER, Chandigarh

Primary Course Coordinators



Dr. Navneet Singh MD DM
Additional Professor of Pulmonary Medicine,
PGIMER, Chandigarh & Secretary, ISSLC
E-mail : navneetd@hotmail.com
Tel. No : +91-172-275-6826



Dr. KT Prasad MD DM
Assistant Professor of Pulmonary
Medicine, PGIMER, Chandigarh
E-mail : docktp@gmail.com
Tel. No. : +91-172-275-6828



Dr. M Valliappan MD DM
Senior Research Associate,
Department of Pulmonary
Medicine, PGIMER, Chandigarh
E-mail : valliappa@gmail.com

Course Coordinators

Dr. CS Pramesh MS
Professor of Surgical Oncology
& Chief, Thoracic Surgery
Tata Memorial Centre, Mumbai
E-mail : prameshcs@tmc.gov.in

Dr. Sabita Jiwnani MS MCh
Assistant Professor of
Surgical Oncology (Thoracic Surgery)
Tata Memorial Centre, Mumbai
E-mail : jiwnanis@tmc.gov.in

Overview of topics To be Covered

- Essentials of Radiological and Nuclear Imaging in Lung Cancer
- Essentials of Pathological and Molecular Testing in Lung Cancer
- Current TNM staging system
- Endoscopic and invasive mediastinal staging in lung cancer
- Management of early stage non-small cell lung cancer (NSCLC) including:
 - Pre-operative assessment for fitness
 - Principles of surgical resection
 - Role of SBRT
- Multimodality management of locally advanced NSCLC including:
 - Trimodality vs. bimodality treatment approaches
 - Neoadjuvant vs. adjuvant treatment approaches
- **Metastatic NSCLC** including:
 - Biomarker Testing and Precision medicine
 - Targeted therapies (EGFR, ALK, ROS1 and beyond) for treatment naïve and pretreated patients
 - Immunotherapy (PD-1/PD-L1 Immune Check Point Inhibitors) – patient selection, PD-L1 testing controversies and specific issues related to imaging and toxicity
 - Chemotherapy regimens – doublets, maintenance, combination with targeted agents
 - Oligoprogression and oligo-metastatic disease
- Small cell lung cancer
- Prognostic factors, comorbidities and elderly patients
- Early integration of palliative care
- Specific interventions for bony and brain metastases
- Guideline Implementation and Adherence in Resource Constrained Settings

Target Audience

This meeting is designed for an audience of MD/MS residents and DM/MCh fellows undergoing training in pathology, pulmonary medicine, thoracic surgery, surgical oncology, medical oncology, radiation oncology and palliative care as well as practitioners in the above mentioned fields. Basically, this is a '**must attend**' and '**not to be missed**' course for any health care professional who is involved in the management of patients with lung cancer.